So far, a few DNA vaccines, such as INO-4800 (Inovio Pharmaceuticals, San Diego, CA, USA), GX-19 (Genexine, Inc., Seoul, Republic of Korea), AG0301-COVID19/AG0302-COVID19 (AnGes, Inc., Osaka, Japan), bacTRL-Spike (Symvivo Corporation, Collingwood North, Australia), and Covigenix VAX-001 (Entos Pharmaceuticals Inc., Alberta, Canada) have been developed with the aim of monoclonal antibody production in vivo via DNA plasmid expressing spike protein into a patient [122]. The gene discussed is CHMP5; the disease is COVID-19.